Cephem-Pyrazinoic Acid Conjugates: Circumventing Resistance in Mycobacterium tuberculosis

Malcolm S. Cole, Michael D. Howe, Joseph A. Buonomo, Sachin Sharma, Elise A. Lamont, Scott I. Brody, Neeraj K. Mishra, Yusuke Minato, Joshua M. Thiede, Anthony D. Baughn, Courtney C. Aldrich

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Tuberculosis (TB) is a leading source of infectious disease mortality globally. Antibiotic-resistant strains comprise an estimated 10 % of new TB cases and present an urgent need for novel therapeutics. β-lactam antibiotics have traditionally been ineffective against M. tuberculosis (Mtb), the causative agent of TB, due to the organism's inherent expression of β-lactamases that destroy the electrophilic β-lactam warhead. We have developed novel β-lactam conjugates, which exploit this inherent β-lactamase activity to achieve selective release of pyrazinoic acid (POA), the active form of a first-line TB drug. These conjugates are selectively active against M. tuberculosis and related mycobacteria, and activity is retained or even potentiated in multiple resistant strains and models. Preliminary mechanistic investigations suggest that both the POA “warhead” as well as the β-lactam “promoiety” contribute to the observed activity, demonstrating a codrug strategy with important implications for future TB therapy.

Original languageEnglish
Article numbere202200995
JournalChemistry - A European Journal
Volume28
Issue number51
DOIs
Publication statusPublished - 12-09-2022

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Cephem-Pyrazinoic Acid Conjugates: Circumventing Resistance in Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this